Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours

• J Dretzke,
• J Round,
• M Connock,
• S Tubeuf,
• M Pennant,
• A Fry-Smith,
• C Hulme,
• C McCabe,
• C Meads

Affiliations

J Dretzke

Unit of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, UK

J Round

Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

M Connock

Unit of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, UK

S Tubeuf

Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

M Pennant

Unit of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, UK

A Fry-Smith

Unit of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, UK

C Hulme

Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

C McCabe

Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

C Meads

Unit of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, UK